|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 1/25/21 Emmaus Life Sciences, Inc. 10-K 12/31/19 121:29M ActiveDisclosure/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 1.84M
2: EX-3.1 Articles of Incorporation/Organization or Bylaws HTML 45K
3: EX-4.1 Instrument Defining the Rights of Security Holders HTML 32K
4: EX-10.11 Material Contract HTML 38K
5: EX-10.12 Material Contract HTML 38K
6: EX-10.23 Material Contract HTML 49K
7: EX-10.25 Material Contract HTML 103K
8: EX-10.26 Material Contract HTML 39K
9: EX-10.27 Material Contract HTML 71K
10: EX-10.28 Material Contract HTML 75K
11: EX-10.29 Material Contract HTML 115K
12: EX-10.30 Material Contract HTML 49K
13: EX-10.33 Material Contract HTML 39K
14: EX-10.34 Material Contract HTML 149K
15: EX-10.35 Material Contract HTML 40K
16: EX-10.37 Material Contract HTML 45K
17: EX-21.1 Subsidiaries List HTML 31K
18: EX-31.1 Certification -- §302 - SOA'02 HTML 36K
19: EX-31.2 Certification -- §302 - SOA'02 HTML 36K
20: EX-32.1 Certification -- §906 - SOA'02 HTML 32K
27: R1 Document and Entity Information HTML 86K
28: R2 Consolidated Balance Sheets HTML 109K
29: R3 Consolidated Balance Sheets (Parenthetical) HTML 47K
30: R4 Consolidated Statements of Operations and HTML 100K
Comprehensive Loss
31: R5 Consolidated Statements of Changes in HTML 97K
Stockholders' Equity (Deficit)
32: R6 Consolidated Statements of Cash Flows HTML 150K
33: R7 Description of Business HTML 39K
34: R8 Summary of Significant Accounting Policies HTML 68K
35: R9 Restatement of Previously Issued Financial HTML 646K
Statements
36: R10 Revenues HTML 120K
37: R11 Selected Financial Statement Captions - Assets HTML 91K
38: R12 Investments HTML 120K
39: R13 Selected Financial Statement Captions - HTML 108K
Liabilities
40: R14 Notes Payable HTML 708K
41: R15 Stockholders' Deficit HTML 432K
42: R16 Income Taxes HTML 144K
43: R17 Leases HTML 65K
44: R18 Commitments and Contingencies HTML 37K
45: R19 Related Party Transactions HTML 489K
46: R20 Subsequent Events HTML 53K
47: R21 Quarterly Financial Statements (Unaudited) HTML 830K
48: R22 Summary of Significant Accounting Policies HTML 131K
(Policies)
49: R23 Restatement of Previously Issued Financial HTML 640K
Statements (Tables)
50: R24 Revenues (Tables) HTML 123K
51: R25 Selected Financial Statement Captions - Assets HTML 96K
(Tables)
52: R26 Investments (Tables) HTML 112K
53: R27 Selected Financial Statement Captions - HTML 109K
Liabilities (Tables)
54: R28 Notes Payable (Tables) HTML 756K
55: R29 Stockholders' Deficit (Tables) HTML 431K
56: R30 Income Taxes (Tables) HTML 146K
57: R31 Leases (Tables) HTML 64K
58: R32 Related Party Transactions (Tables) HTML 487K
59: R33 Subsequent Events (Tables) HTML 38K
60: R34 Quarterly Financial Statements (Unaudited) HTML 828K
(Tables)
61: R35 Description of Business (Details Narrative) HTML 48K
62: R36 Summary of Significant Accounting Policies HTML 56K
(Details Narrative)
63: R37 Restatement of Previously Issued Financial HTML 102K
Statements (Details Narrative)
64: R38 Restatement of Previously Issued Financial HTML 172K
Statements (Details 1)
65: R39 Restatement of Previously Issued Financial HTML 123K
Statements (Parenthetical) (Details 1)
66: R40 Restatement of Previously Issued Financial HTML 163K
Statements (Details 2)
67: R41 Restatement of Previously Issued Financial HTML 98K
Statements (Parenthetical) (Details 2)
68: R42 Restatement of Previously Issued Financial HTML 201K
Statements (Details 3)
69: R43 Restatement of Previously Issued Financial HTML 41K
Statements (Parenthetical) (Details 3)
70: R44 Revenues (Details) HTML 37K
71: R45 Revenues (Details 1) HTML 45K
72: R46 Revenues (Details 2) HTML 41K
73: R47 Revenues (Details Narrative) HTML 41K
74: R48 Selected Financial Statement Captions - Assets HTML 40K
(Details)
75: R49 Selected Financial Statement Captions - Assets HTML 37K
(Details 1)
76: R50 Selected Financial Statement Captions - Assets HTML 45K
(Details 2)
77: R51 Selected Financial Statement Captions - Assets HTML 32K
(Details Narrative)
78: R52 Investments (Details Narrative) HTML 85K
79: R53 Investments (Details 1) HTML 38K
80: R54 Investments (Details 2) HTML 59K
81: R55 Selected Financial Statement Captions - HTML 65K
Liabilities (Details)
82: R56 Selected Financial Statement Captions - HTML 39K
Liabilities (Details 1)
83: R57 Selected Financial Statement Captions - HTML 42K
Liabilities (Details Narrative)
84: R58 Notes Payable (Details) HTML 109K
85: R59 Notes Payable (Details 1) HTML 63K
86: R60 Notes Payable (Details 2) HTML 130K
87: R61 Notes Payable (Details Narrative) HTML 57K
88: R62 Notes Payable (Details 3) HTML 40K
89: R63 Notes Payable (Details 4) HTML 56K
90: R64 Stockholders' Deficit (Details Narrative) HTML 161K
91: R65 Stockholders' Deficit (Details) HTML 38K
92: R66 Stockholders' Deficit (Details 1) HTML 51K
93: R67 Stockholders' Deficit (Details 2) HTML 42K
94: R68 Stockholders' Deficit (Details 3) HTML 51K
95: R69 Stockholders' Deficit (Details 4) HTML 42K
96: R70 Stockholders' Deficit (Details 5) HTML 89K
97: R71 Stockholders' Deficit (Parenthetical) (Details 5) HTML 31K
98: R72 Stockholders' Deficit (Details 6) HTML 41K
99: R73 Stockholders' Deficit (Details 7) HTML 59K
100: R74 Income Taxes (Details) HTML 39K
101: R75 Income Taxes (Details 1) HTML 58K
102: R76 Income Taxes (Details 2) HTML 39K
103: R77 Income Taxes (Details Narrative) HTML 47K
104: R78 Income Taxes (Details 3) HTML 49K
105: R79 Leases (Details Narrative) HTML 66K
106: R80 Leases (Details) HTML 46K
107: R81 Leases (Details 1) HTML 45K
108: R82 Commitments and Contingencies (Details Narrative) HTML 71K
109: R83 Related Party Transactions (Details) HTML 133K
110: R84 Related Party Transactions (Details Narrative) HTML 36K
111: R85 Subsequent Events (Details) HTML 41K
112: R86 Subsequent Events (Details Narrative) HTML 143K
113: R87 Quarterly Financial Statements (Unaudited) HTML 162K
(Details 1)
114: R88 Quarterly Financial Statements (Unaudited) HTML 119K
(Parenthetical) (Details 1)
115: R89 Quarterly Financial Statements (Unaudited) HTML 173K
(Details 2)
116: R90 Quarterly Financial Statements (Unaudited) HTML 102K
(Parenthetical) (Details 2)
117: R91 Quarterly Financial Statements (Unaudited) HTML 193K
(Details 3)
118: R92 Quarterly Financial Statements (Unaudited) HTML 37K
(Details Narrative)
120: XML IDEA XML File -- Filing Summary XML 211K
119: EXCEL IDEA Workbook of Financial Reports XLSX 195K
21: EX-101.INS XBRL Instance -- emma-20191231 XML 9.60M
23: EX-101.CAL XBRL Calculations -- emma-20191231_cal XML 341K
24: EX-101.DEF XBRL Definitions -- emma-20191231_def XML 1.45M
25: EX-101.LAB XBRL Labels -- emma-20191231_lab XML 1.94M
26: EX-101.PRE XBRL Presentations -- emma-20191231_pre XML 2.05M
22: EX-101.SCH XBRL Schema -- emma-20191231 XSD 296K
121: ZIP XBRL Zipped Folder -- 0001564590-21-001977-xbrl Zip 385K
Exhibit 3.1
RESTATED CERTIFICATE OF INCORPORATION
OF
EMMAUS LIFE SCIENCES, INC.
(Originally incorporated on March 20, 1987
under the name of AGE RESEARCH, INC.)
ARTICLE I
The name of the corporation is Emmaus Life Sciences, Inc. (the “Corporation”).
ARTICLE II
The registered office of the Corporation in the State of Delaware is 9 E. Loockerman Street, Suite 311, Dover, Delaware 19901, County of Kent. The registered agent in charge thereof at such address is Registered Agent Solutions, Inc.
ARTICLE III
The nature of the business, and the objects and purposes proposed to be transacted, promoted and carried on, are to do any or all things herein mentioned, as fully and to the same extent as natural persons might or could do, and in any part of the world, viz.:
“The purpose of the Corporation is to engage in any lawful act or activity for which corporations may be organized under the General Corporation Law of Delaware.”
ARTICLE IV
CAPITAL STOCK
Section 4.A. The total number of shares of stock which the Corporation shall have authority to issue is Two Hundred Sixty Five Million (265,000,000).
Section 4.B. Common Stock. The total number of shares of Common Stock which the Corporation shall have authority to issue is Two Hundred and Fifty Million (250,000,000), with a par value of $0.001 per share. Stockholders shall not have preemptive rights or be entitled to cumulative voting in connection with the shares of the Corporation’s Common Stock.
Section 4.C. Blank-Check Preferred Stock. The total number of shares of undesignated preferred stock which the Corporation shall have the authority to issue is Fifteen Million (15,000,000) shares, with a par value of $0.001 per share. The Board of Directors is hereby expressly authorized to provide, out of the unissued shares of preferred stock, for one or more series of preferred stock and, with respect to each such series, to fix the number of shares constituting such series and the designation of such series, the voting powers, if any, of the shares of such series, and the preferences and relative, participating, optional or other special rights, if
any, and any qualifications, limitations or restrictions thereof, of the shares of such series. The powers, preferences and relative, participating, optional and other special rights of each series of preferred stock, and the qualifications, limitations or restrictions thereof, if any, may differ from those of any and all other series at any time outstanding.
ARTICLE V
[Reserved.]
ARTICLE VI
The number of members of the Board of Directors shall be fixed from time to time by the Board of Directors. If any vacancy occurs, the remaining directors, by an affirmative vote of a majority thereof, may elect a director to fill the vacancy until the next annual meeting of stockholders.
ARTICLE VII
No contract or transaction between the Corporation and one or more of its directors or officers, or between the Corporation and any other corporation, partnership, association, or other organization in which one or more of its directors or officers are directors or officers, or have a financial interest, shall be void or voidable solely for this reason, or solely because the director or officer is present at or participates in the meeting of the Board of Directors or committee thereof which authorizes the contract or transaction, or solely because his or their votes are counted for such purpose, if:
1. The material facts as to his interest and as to the contract or transaction are disclosed or are known to the Board of Directors or the Committee, and the Board or committee in good faith authorizes the contract or transaction by a vote sufficient for such purpose without counting the vote of the interested director or directors; or
2. The material facts as to his interest and as to the contract or transaction are disclosed or are known to the stockholders entitled to vote thereon, and the contract or transaction is specifically approved in good faith by vote of the stockholders; or
3. The contract or transaction is fair as to the Corporation as of the time it is authorized, approved or ratified, by the Board of Directors, a committee thereof, or the stockholders.
Interested directors may be counted in determining the presence of a quorum at a meeting of the Board of Directors or of a committee which authorizes the contract or transaction.
ARTICLE VIII
The Board of Directors shall have the power to make, adopt, amend or repeal the Bylaws of the Corporation.
2
Section 1. Elimination of Certain Liability of Directors. A director of the Corporation shall not be personally liable to the Corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except for liability (i) for any breach of the director’s duty of loyalty to the Corporation or its stockholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law (iii) under Section 174 of the Delaware General Corporation Law, or (iv) for any transaction from which the director derived an improper personal benefit.
Section 2. Indemnification and Insurance.
(a) Right to Indemnification. Each person who was or is made a party or is threatened to be made a party or is involved in any action, suit or proceeding, whether civil, criminal, administrative or investigative (hereinafter a “proceeding”), by reason of the fact that he or she, or a person of whom he or she is the legal representative, is or was a director or officer of the Corporation or is or was serving at the request of the Corporation as a director, officer, employee or agent of another corporation or of a partnership, joint venture, trust or other enterprise, including service with respect to employee benefit plans, whether the basis of such proceeding is alleged action in an official capacity as a director, officer, employee or agent or in any other capacity while serving as a director, officer, employee or agent, shall be indemnified and held harmless by the Corporation to the fullest extent authorized by the Delaware General Corporation Law, as the same exists or may hereafter be amended (but, in the case of any such amendment, only to the extent that such amendment permits the Corporation to provide broader indemnification rights than said law permitted the Corporation to provide prior to such amendment), against all expense, liability and loss (including attorney’s fees, judgments, fines, ERISA excise taxes or penalties and amounts paid or to be paid in settlement) reasonably incurred or suffered by such person in connection therewith and such indemnification shall continue as to a person who has ceased to be a director, officer, employee or agent and shall inure to the benefit of his or her heirs, executors and administrators; provided, however, that, except as provided in paragraph (b) hereof, the Corporation shall indemnify any such person seeking indemnification in connection with a proceeding (or part thereof) initiated by such person only if such proceeding (or part thereof) was authorized by the Board of Directors of the Corporation. The right to indemnification conferred in this Section shall be a contract right and shall include the right to be paid by the Corporation the expenses incurred in defending any such proceeding in advance of its final disposition; provided, however, that, if the Delaware General Corporation Law requires, the payment of such expenses incurred by a director or officer in his or her capacity as a director or officer (and not in any other capacity in which service was or is rendered by such person while a director or officer including, without limitation, service to an employee benefit plan) in advance of the final disposition of a proceeding, shall be made only upon delivery to the corporation of an undertaking, by or on behalf of such director or officer, to repay all amounts so advanced if it shall ultimately be determined that such director or officer is not entitled to be indemnified under this Section or otherwise. The Corporation may, by action of its Board of Directors, provide indemnification to employees and agents of the Corporation with the same scope and effect as the foregoing indemnification of directors and officers.
3
(b) Right of Claimant to Bring Suit. If a claim under paragraph (a) of this Section is not paid in full by the Corporation within 30 days after a written claim has been received by the Corporation, the claimant may at any time thereafter bring suit against the Corporation to recover the unpaid amount of the claim and, if successful in whole or in part, the claimant shall be entitled to be paid also the expense of prosecuting such claim. It shall be a defense to any such action (other than an action brought to enforce a claim for expenses incurred in defending any proceeding in advance of its final disposition where the required undertaking, if any is required, has been tendered to the Corporation) that the claimant has not met the standards of conduct which make it permissible under the Delaware General Corporation Law for the Corporation to indemnify the claimant for the amount claimed, but the burden of proving such defense shall be on the Corporation. Neither the failure of the Corporation (including its Board of Directors, independent legal counsel, or its stockholders) to have made a determination prior to the commencement of such action that indemnification of the claimant is proper in the circumstances because he or she has met the applicable standard of conduct set forth in the Delaware General Corporation Law, nor an actual determination by the Corporation (including its Board of Directors, independent legal counsel, or its stockholders) that the claimant has not met such applicable standard of conduct, shall be a defense to the action or create a presumption that the claimant has not met the applicable standard of conduct.
(c) Non-Exclusivity of Rights. The right to indemnification and the payment of expenses incurred in defending a proceeding in advance of its final disposition conferred in this Section shall not be exclusive of any other right which any person may have or hereafter acquire under any statute, provision of the Certificate of Incorporation, bylaw, agreement, vote of stockholders or disinterested directors or otherwise.
(d) Insurance. The Corporation may maintain insurance, at its expense, to protect itself and any director, officer, employee or agent of the Corporation or another corporation, partnership, joint venture, trust or other enterprise against any such expense, liability or loss, whether or not the Corporation would have the power to indemnify such person against such expense, liability or loss under the Delaware General Corporation Law.
[Signature Page Follows]
4
In witness whereof, this Restated Certificate of Incorporation which only restates and integrates and does not further amend the provisions of the Certificate of Incorporation of the Corporation as heretofore amended or supplemented, there being no discrepancies between those provisions and the provisions of this Restated Certificate of Incorporation, and it having been duly adopted by the Corporation’s Board of Directors in accordance with Section 245 of the Delaware General Corporation Law, has been executed by its duly authorized officer this 5th day of November, 2019.
EMMAUS LIFE SCIENCES, INC.
By: /S/YUTAKA NIIHARA_________________
Name: Yutaka Niihara, M.D., M.P.H.
Title: Chairman and Chief Executive Officer
5
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/31/23 Emmaus Life Sciences, Inc. 10-K 12/31/22 88:18M Donnelley … Solutions/FA 3/31/22 Emmaus Life Sciences, Inc. 10-K 12/31/21 98:18M ActiveDisclosure/FA 12/30/21 Emmaus Life Sciences, Inc. S-8 12/30/21 6:155K EdgarAgents LLC/FA 8/10/21 Emmaus Life Sciences, Inc. 10-K/A 12/31/20 92:18M ActiveDisclosure/FA 5/04/21 Emmaus Life Sciences, Inc. 10-K 12/31/20 97:18M ActiveDisclosure/FA |